CITIUS ONCOLOGY, INC. (CTOR)

SEC fundamentals · as filed in 10-Q FY2026, period ended Jun 30, 2026 · updated Oct 7, 2026

Verified against EDGAR
Total Assets
$112.1M
Stockholders' Equity
$40.4M
Cash & Equivalents
$16.6M
Long-Term Debt
—

as filed in 10-Q FY2026, period ended Jun 30, 2026 · View filings on EDGAR ↗

In its 10-Q for the period ended Jun 30, 2026, CITIUS ONCOLOGY, INC. reported revenue of $1.5M, net income of -$8.9M, and total assets of $112.1M. Every figure below is taken directly from CITIUS ONCOLOGY, INC.'s SEC filings: each links to the source document on EDGAR.

Revenue and net income by fiscal year

As reported in each year’s annual filing · USD

Fiscal yearRevenueNet income
FY2025—-$24.8M
FY2024—-$21.1M
FY2023—$2.4M
FY2022—$380,811

Recent SEC filings

Filed by the registrant · newest first · insider forms and holder schedules not included

FormFiledSource
8-KOct 26, 2026on EDGAR ↗
8-KOct 23, 2026on EDGAR ↗
8-KSep 29, 2026on EDGAR ↗
DEF 14AAug 26, 2026on EDGAR ↗
8-KAug 14, 2026on EDGAR ↗
10-QAug 14, 2026on EDGAR ↗
8-KAug 12, 2026on EDGAR ↗
8-KAug 5, 2026on EDGAR ↗
8-KJun 1, 2026on EDGAR ↗
8-KMay 15, 2026on EDGAR ↗

All filings on EDGAR ↗

Balance Sheet

as of Jun 30, 2026 · 10-Q

Total Assets$112.1Msource ↗
Stockholders’ Equity$40.4Msource ↗
Cash & Equivalents$16.6Msource ↗
Long-Term Debt—source ↗

Income Statement

10-Q (quarterly) · period ended Jun 30, 2026

Revenue$1.5Msource ↗
Net Income-$8.9Msource ↗
Operating Income-$8.7Msource ↗
Gross Profit$1.0Msource ↗
Cost of Revenue$491,843source ↗
R&D Expense$218,496source ↗

Per Share & Cash Flow

10-Q (quarterly) · period ended Jun 30, 2026

EPS (diluted)$-0.08source ↗
EPS (basic)$-0.08source ↗
Shares Outstanding93.0Msource ↗
Cash from Operations-$2.7Msource ↗
Cash from Financing$18.6Msource ↗
Cash from Investing-$2.0Msource ↗

Restatement history

Point-in-time

1 of 97 annual fact-keys were materially restated between filings: what CITIUS ONCOLOGY, INC. first reported differed from what it later filed. We keep every vintage of every annual figure, each keyed to its EDGAR accession.

See each original-vs-restated value, and query any company as of any past date, with the point-in-time API.

See the restatement detail →

Deeper fundamentals

A free API key reaches CTOR’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.

Get a free API key →See plans

Programmatic access

Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.

These fundamentals, as filed
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/fundamentals/CTOR

MCP tool: get_sec_fundamentals ticker=CTOR

The same figures as they were known on any past date
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/fundamentals/CTOR/as-of/YYYY-MM-DD

MCP tool: get_asof_fundamentals ticker=CTOR as_of=YYYY-MM-DD

Fiscal-year trajectory: revenue, margins, free cash flow
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/fundamentals/CTOR/history

MCP tool: get_fundamentals_history ticker=CTOR

Leverage, liquidity, margin and return ratios
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/financial-health/CTOR

MCP tool: get_financial_health ticker=CTOR

Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.